tradingview.comNov 4

Key facts: Evonik EBITDA Up 40%; No BASF Talks; Prepares Unit Sales

Evonik reported Q3 sales of €3.83B, up 13%, and adjusted EBITDA of €629M, up 40%. The company expects 2026 EBITDA between €2.0B and €2.2B. Evonik denied takeover talks with BASF and plans to sell its Oxeno unit and potentially Syneqt. It is also investing €52M to expand its silicone platform in Essen.

Original reporting

tradingview.com

Published Nov 4, 2026, 6:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 4, 2026, 6:10 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Key facts: Evonik EBITDA Up 40%; No BASF Talks; Prepares Unit Sales — source image — Source · tradingview.com

Decision brief

The 30-second read

Med

Why it matters

The earnings beat and raised guidance are likely to drive short‑term buying interest, especially in Europe.

Market read

First report of Evonik's Q3 results; material earnings surprise for a mid‑cap European stock.

What to watch

Potential headwinds from raw‑material cost inflation and BASF's rumored interest could temper gains.

Relevance 7/10Novelty 7/10Timing: pre‑market Europe

Background

Evonik Industries AG (EVK) is a German specialty chemicals producer. The article summarizes its Q3 performance and future EBITDA guidance.

Market effects

Sector

Boosts outlook for the European specialty chemicals sector as earnings beat may lift peers.

Regional

Supports German DAX sentiment amid broader earnings season.

Global

Limited to chemicals; no direct global macro effect.

Counterpoint

What could challenge this read

If the market had already priced in a strong rebound, the upside may be muted.

Key entities

company
Evonik Industries AG
German specialty chemicals manufacturer

Read at source ← All news

Med

Jefferies cuts Evonik as Middle East disruption boost to earnings fades

Jefferies downgraded Evonik Industries to 'hold' and cut its 2027 EBITDA forecast by 9% to below €2 billion. The brokerage raised its price target to €21 and noted that share price movements may depend on potential engagement with BASF. Evonik's EBITDA is up 14% year-to-date, but Jefferies sees challenges in reaching its 2029 ROCE target.

investing.comNov 11

$EVKIFMedAI 8/10

Evonik Industries reports Q3 results (OTCMKTS:EVKIF)

Evonik Industries reported a 13% sales increase in Q3, its largest quarterly gain since Q3 2022. The company expects 2026 adjusted EBITDA to be in the upper half of its €2.0B to €2.2B range. Evonik recently rejected a $12.5B takeover bid from BASF but is open to informational talks.

seekingalpha.comNov 3

HighAI 8/10

Evonik Q3 2026 slides: EBITDA surges 40%, ROCE target upgraded

Evonik Industries reported Q3 2026 results with 40% EBITDA growth and 13% sales increase. Advanced Technologies segment surged 87% while free cash flow doubled. The company upgraded its ROCE guidance to over 8% for 2026, aiming for 11% by 2029. Shares traded at $20.82, up 0.39%.

investing.comNov 3

HighAI 8/10

Evonik's losses shrink as core earnings surge 40%

Evonik Industries reported a narrower net loss of €53M in Q3, down from €106M a year ago, with net sales up 13% to €3.83B. Adjusted EBITDA surged 40% to €629M. The company expects full-year adjusted EBITDA at the upper end of its €2B-€2.2B range.

finance.yahoo.comNov 3

$EVKIFMed

Evonik rejects BASF’s $12.5B takeover bid but leaves opening for 'purely informational' talks

Evonik Industries rejected BASF's €11.2B takeover bid but left the door open for informational talks. Evonik's shares fell 1.2% in European trading. BASF's offer was for Germany's second-largest chemical maker.

seekingalpha.comOct 30

$BAS.DEHighAI 9/10

Evonik rejects BASF takeover approach, opts to stay independent

Evonik Industries rejected a takeover approach from BASF, opting to remain independent. BASF had proposed a valuation of over €11 billion, up from €10.3 billion, with commitments to preserve jobs and production sites. Evonik's board reviewed the offer but decided against negotiations, reaffirming its strategic independence.

investing.comOct 30